The leading medical-aesthetic care network, Epiderma, is equipping its clinics with the new generation VelaShape III unit, a state-of-the-art technology for the treatment of cellulite and body contouring.
Representing an initial investment of roughly $85,000 per clinic, for a total exceeding $2 million, this move is part of an extensive equipment renewal plan introduced by Epiderma for 2019–2020.
“We are always on the lookout for the most effective and safest technologies on the market, and we are proud to acquire the VelaShape III to benefit our clients. Over the years, our experience with Candela medical devices has proven to be very positive which, among many other factors, was considered when making our choice,” says Pierre Montminy, President of Epiderma.
Significant benefits to clients
Based on the trials conducted by Epiderma, the VelaShape III delivers significant benefits to clients such as:
- treatments with little to no discomfort or pain;
- noticeably better results;
- significantly shorter sessions and treatment plans.
The cellulite treatment plan will no longer require 10 sessions, but only 6 while the body contouring plan will require 4 instead of 10.
Clinically tested for more than ten years with 5 million independent treatments worldwide, VelaShape is a body treatment solution for body contouring. This is the only non-invasive treatment approved by the FDA to reduce the appearance of cellulite and the circumference of the treated area. This technology has been the subject of the largest number of published studies on medical body remodeling devices with a 97% satisfaction rate among those treated.